أعرض في EDS

Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody

التفاصيل البيبلوغرافية
العنوان:	Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody
المؤلفون:	Kazushige Wakuda, Satoshi Ikeda, Masafumi Sata, Ryota Ushio, Kentaro Ito, Takashi Sato, Shigeru Tanzawa, Naoki Furuya, Makoto Nishino
المصدر:	Thoracic Cancer Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021)
سنة النشر:	2020
مصطلحات موضوعية:	0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Adult, Male, atezolizumab, non‐small cell lung cancer, medicine.medical_specialty, Lung Neoplasms, Pembrolizumab, Antibodies, Monoclonal, Humanized, lcsh:RC254-282, Cohort Studies, 03 medical and health sciences, anti‐PD‐L1, 0302 clinical medicine, Atezolizumab, Internal medicine, Carcinoma, Non-Small-Cell Lung, medicine, Humans, Lung cancer, Immune Checkpoint Inhibitors, Aged, Retrospective Studies, Aged, 80 and over, Performance status, business.industry, Anti pd 1, General Medicine, Original Articles, Middle Aged, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Confidence interval, 030104 developmental biology, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Female, Original Article, Nivolumab, business, Cohort study
الوصف:	Background Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity. Some real‐world efficacy and safety studies of anti‐PD‐1 antibody have been previously reported. However, there have been no reports investigating the efficacy of atezolizumab monotherapy in clinical practice which have focused on performance status and previous anti‐PD‐1 antibody treatment. Methods We retrospectively reviewed consecutive advanced NSCLC patients who received atezolizumab monotherapy between April 2018 and February 2019 at eight institutions. A total of 152 patients with NSCLC were enrolled in this study. Results A total of 38 patients (25%) had already been treated with anti‐PD‐1 treatment (nivolumab or pembrolizumab) before atezolizumab. The median OS and TTF was 384 days (12.8 months) (95% confidence interval [CI]: 206–424), and 42 days (1.4 months) (95% CI: 27–56) in all patients, respectively. ECOG PS 0 had significantly longer OS (median OS; not reached, p Swimmers plot of atezolizumab according to the efficacy of prior anti‐PD‐1 treatment. Seven patients (18.4%, 7/38) continued atezolizumab over four months as an ICI retreatment.
تدمد:	1759-7714
الوصول الحر:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3Test https://pubmed.ncbi.nlm.nih.gov/33448648Test
حقوق:	OPEN
رقم الانضمام:	edsair.doi.dedup.....12194075aa42c60389387090977b3ce3
قاعدة البيانات:	OpenAIRE

ResultId	1
Header	edsair OpenAIRE edsair.doi.dedup.....12194075aa42c60389387090977b3ce3 853 3 unknown 852.626953125
PLink	https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....12194075aa42c60389387090977b3ce3&custid=s6537998&authtype=sso
FullText	Array ( [Availability] => 0 )
Items	Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody ) Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Kazushige+Wakuda%22">Kazushige Wakuda</searchLink><br /><searchLink fieldCode="AR" term="%22Satoshi+Ikeda%22">Satoshi Ikeda</searchLink><br /><searchLink fieldCode="AR" term="%22Masafumi+Sata%22">Masafumi Sata</searchLink><br /><searchLink fieldCode="AR" term="%22Ryota+Ushio%22">Ryota Ushio</searchLink><br /><searchLink fieldCode="AR" term="%22Kentaro+Ito%22">Kentaro Ito</searchLink><br /><searchLink fieldCode="AR" term="%22Takashi+Sato%22">Takashi Sato</searchLink><br /><searchLink fieldCode="AR" term="%22Shigeru+Tanzawa%22">Shigeru Tanzawa</searchLink><br /><searchLink fieldCode="AR" term="%22Naoki+Furuya%22">Naoki Furuya</searchLink><br /><searchLink fieldCode="AR" term="%22Makoto+Nishino%22">Makoto Nishino</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Thoracic Cancer<br />Thoracic Cancer, Vol 12, Iss 5, Pp 613-618 (2021) ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%220301+basic+medicine%22">0301 basic medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Pulmonary+and+Respiratory+Medicine%22">Pulmonary and Respiratory Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Oncology%22">Oncology</searchLink><br /><searchLink fieldCode="DE" term="%22Adult%22">Adult</searchLink><br /><searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22atezolizumab%22">atezolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22non‐small+cell+lung+cancer%22">non‐small cell lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+Neoplasms%22">Lung Neoplasms</searchLink><br /><searchLink fieldCode="DE" term="%22Pembrolizumab%22">Pembrolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%2C+Humanized%22">Antibodies, Monoclonal, Humanized</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3ARC254-282%22">lcsh:RC254-282</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+Studies%22">Cohort Studies</searchLink><br /><searchLink fieldCode="DE" term="%2203+medical+and+health+sciences%22">03 medical and health sciences</searchLink><br /><searchLink fieldCode="DE" term="%22anti‐PD‐L1%22">anti‐PD‐L1</searchLink><br /><searchLink fieldCode="DE" term="%220302+clinical+medicine%22">0302 clinical medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Atezolizumab%22">Atezolizumab</searchLink><br /><searchLink fieldCode="DE" term="%22Internal+medicine%22">Internal medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Carcinoma%2C+Non-Small-Cell+Lung%22">Carcinoma, Non-Small-Cell Lung</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22Lung+cancer%22">Lung cancer</searchLink><br /><searchLink fieldCode="DE" term="%22Immune+Checkpoint+Inhibitors%22">Immune Checkpoint Inhibitors</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%22">Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Retrospective+Studies%22">Retrospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22Aged%2C+80+and+over%22">Aged, 80 and over</searchLink><br /><searchLink fieldCode="DE" term="%22Performance+status%22">Performance status</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Anti+pd+1%22">Anti pd 1</searchLink><br /><searchLink fieldCode="DE" term="%22General+Medicine%22">General Medicine</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Articles%22">Original Articles</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22lcsh%3ANeoplasms%2E+Tumors%2E+Oncology%2E+Including+cancer+and+carcinogens%22">lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens</searchLink><br /><searchLink fieldCode="DE" term="%22Confidence+interval%22">Confidence interval</searchLink><br /><searchLink fieldCode="DE" term="%22030104+developmental+biology%22">030104 developmental biology</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Resistance%2C+Neoplasm%22">Drug Resistance, Neoplasm</searchLink><br /><searchLink fieldCode="DE" term="%22030220+oncology+%26+carcinogenesis%22">030220 oncology & carcinogenesis</searchLink><br /><searchLink fieldCode="DE" term="%22Retreatment%22">Retreatment</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Article%22">Original Article</searchLink><br /><searchLink fieldCode="DE" term="%22Nivolumab%22">Nivolumab</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22Cohort+study%22">Cohort study</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Background Atezolizumab is a programmed death‐ligand 1 (PD‐L1) targeted monoclonal antibody that inhibits PD‐L1 interacting with its receptors PD‐1 and B7‐1, thereby enhancing anticancer immunity. Some real‐world efficacy and safety studies of anti‐PD‐1 antibody have been previously reported. However, there have been no reports investigating the efficacy of atezolizumab monotherapy in clinical practice which have focused on performance status and previous anti‐PD‐1 antibody treatment. Methods We retrospectively reviewed consecutive advanced NSCLC patients who received atezolizumab monotherapy between April 2018 and February 2019 at eight institutions. A total of 152 patients with NSCLC were enrolled in this study. Results A total of 38 patients (25%) had already been treated with anti‐PD‐1 treatment (nivolumab or pembrolizumab) before atezolizumab. The median OS and TTF was 384 days (12.8 months) (95% confidence interval [CI]: 206–424), and 42 days (1.4 months) (95% CI: 27–56) in all patients, respectively. ECOG PS 0 had significantly longer OS (median OS; not reached, p<br />Swimmers plot of atezolizumab according to the efficacy of prior anti‐PD‐1 treatment. Seven patients (18.4%, 7/38) continued atezolizumab over four months as an ICI retreatment. ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1759-7714 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12194075aa42c60389387090977b3ce3</link><br /><link linkTarget="URL" linkTerm="https://pubmed.ncbi.nlm.nih.gov/33448648" linkWindow="_blank">https://pubmed.ncbi.nlm.nih.gov/33448648</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....12194075aa42c60389387090977b3ce3 )
RecordInfo	Array ( [BibEntity] => Array ( [Languages] => Array ( [0] => Array ( [Text] => Undetermined ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => 0301 basic medicine [Type] => general ) [1] => Array ( [SubjectFull] => Pulmonary and Respiratory Medicine [Type] => general ) [2] => Array ( [SubjectFull] => Oncology [Type] => general ) [3] => Array ( [SubjectFull] => Adult [Type] => general ) [4] => Array ( [SubjectFull] => Male [Type] => general ) [5] => Array ( [SubjectFull] => atezolizumab [Type] => general ) [6] => Array ( [SubjectFull] => non‐small cell lung cancer [Type] => general ) [7] => Array ( [SubjectFull] => medicine.medical_specialty [Type] => general ) [8] => Array ( [SubjectFull] => Lung Neoplasms [Type] => general ) [9] => Array ( [SubjectFull] => Pembrolizumab [Type] => general ) [10] => Array ( [SubjectFull] => Antibodies, Monoclonal, Humanized [Type] => general ) [11] => Array ( [SubjectFull] => lcsh:RC254-282 [Type] => general ) [12] => Array ( [SubjectFull] => Cohort Studies [Type] => general ) [13] => Array ( [SubjectFull] => 03 medical and health sciences [Type] => general ) [14] => Array ( [SubjectFull] => anti‐PD‐L1 [Type] => general ) [15] => Array ( [SubjectFull] => 0302 clinical medicine [Type] => general ) [16] => Array ( [SubjectFull] => Atezolizumab [Type] => general ) [17] => Array ( [SubjectFull] => Internal medicine [Type] => general ) [18] => Array ( [SubjectFull] => Carcinoma, Non-Small-Cell Lung [Type] => general ) [19] => Array ( [SubjectFull] => medicine [Type] => general ) [20] => Array ( [SubjectFull] => Humans [Type] => general ) [21] => Array ( [SubjectFull] => Lung cancer [Type] => general ) [22] => Array ( [SubjectFull] => Immune Checkpoint Inhibitors [Type] => general ) [23] => Array ( [SubjectFull] => Aged [Type] => general ) [24] => Array ( [SubjectFull] => Retrospective Studies [Type] => general ) [25] => Array ( [SubjectFull] => Aged, 80 and over [Type] => general ) [26] => Array ( [SubjectFull] => Performance status [Type] => general ) [27] => Array ( [SubjectFull] => business.industry [Type] => general ) [28] => Array ( [SubjectFull] => Anti pd 1 [Type] => general ) [29] => Array ( [SubjectFull] => General Medicine [Type] => general ) [30] => Array ( [SubjectFull] => Original Articles [Type] => general ) [31] => Array ( [SubjectFull] => Middle Aged [Type] => general ) [32] => Array ( [SubjectFull] => medicine.disease [Type] => general ) [33] => Array ( [SubjectFull] => lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens [Type] => general ) [34] => Array ( [SubjectFull] => Confidence interval [Type] => general ) [35] => Array ( [SubjectFull] => 030104 developmental biology [Type] => general ) [36] => Array ( [SubjectFull] => Drug Resistance, Neoplasm [Type] => general ) [37] => Array ( [SubjectFull] => 030220 oncology & carcinogenesis [Type] => general ) [38] => Array ( [SubjectFull] => Retreatment [Type] => general ) [39] => Array ( [SubjectFull] => Female [Type] => general ) [40] => Array ( [SubjectFull] => Original Article [Type] => general ) [41] => Array ( [SubjectFull] => Nivolumab [Type] => general ) [42] => Array ( [SubjectFull] => business [Type] => general ) [43] => Array ( [SubjectFull] => Cohort study [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Real-world efficacy of atezolizumab in non-small cell lung cancer: A multicenter cohort study focused on performance status and retreatment after failure of anti-PD-1 antibody [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kazushige Wakuda ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Satoshi Ikeda ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Masafumi Sata ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Ryota Ushio ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kentaro Ito ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Takashi Sato ) ) ) [6] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Shigeru Tanzawa ) ) ) [7] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Naoki Furuya ) ) ) [8] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Makoto Nishino ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 28 [M] => 11 [Type] => published [Y] => 2020 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 17597714 ) [1] => Array ( [Type] => issn-locals [Value] => edsair ) [2] => Array ( [Type] => issn-locals [Value] => edsairFT ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 12 ) [1] => Array ( [Type] => issue [Value] => 5 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Thoracic cancer [Type] => main ) ) ) ) ) ) )
IllustrationInfo